Key Highlights:
- Servier has selected India as the base for its global platform GATINN, supported by an investment of around €15 million. The initiative combines Servier’s research expertise in France with India’s strong manufacturing and drug-development ecosystem.
- The platform will focus on developing Single-Pill Combinations (SPCs) that combine multiple medicines into one daily tablet, helping improve treatment adherence for chronic cardiometabolic and venous diseases. By coordinating development, manufacturing, supply chain and quality oversight from India, Servier aims to accelerate delivery of these therapies.
- Designed as an export-focused hub, GATINN will supply medicines to markets across Asia, Latin America, Africa and the Middle East. Servier plans to have around five SPC products in development by 2026, with the first international launch expected in Q2 2027.
Implications:
India’s GATINN catapults Servier into SPC dominance, crushing fragmented chronic therapy rivals while exploding patient compliance across emerging markets.
Local development muscle slashes costs and timelines, handing Servier killer edge over Big Pharma’s complex combos in diabetes/heart failure battlegrounds.
Source: ET pharma | Image: Servier
Other Articles
Previous
No Comment! Be the first one.